45 results
8-K
SLRN
Acelyrin, Inc.
13 Aug 24
Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results
4:14pm
million in cash-based expenses related to employee severance payments and benefits related to the workforce reduction. The Company expects … (the “Separation Agreement”), pursuant to which the Company agreed to provide Ms. Gloria with certain severance benefits, including the following: a lump sum
8-K
EX-10.1
SLRN
Acelyrin, Inc.
13 Aug 24
Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results
4:14pm
and benefits and will work cooperatively with the Company to continue to perform current job duties, as well as to transition Employee’s various roles … terminate, and Employee
will not receive any of the separation benefits described herein, in the event that Employee voluntarily resigns her employment
8-K/A
SLRN
Acelyrin, Inc.
28 May 24
Departure of Directors or Certain Officers
5:20pm
benefits, including the following: a lump sum payment equal to approximately 18 months of base salary, approximately 18 months of equity award … level, which provides Ms. Kim with the same severance benefits as previously provided to Dr. Lin under the Severance Plan, which benefits are described
DEFA14A
d6qdiuge4 rxfyxvdi34
9 May 24
Additional proxy soliciting materials
8:14am
8-K
4hczt3dj
9 May 24
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
8:13am
8-K
EX-10.2
opa8scb
9 May 24
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
8:13am
8-K
EX-99.1
5nkh5y
9 May 24
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
8:13am
8-K
EX-10.1
79j0d7qpby
9 May 24
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
8:13am
DEF 14A
m1gb5fctxy4w4z sp
22 Apr 24
Definitive proxy
4:10pm
10-K
8yt gfhs9d87fnmx6ip8
28 Mar 24
Annual report
4:21pm
10-K
EX-4.3
kmy9xnc5
28 Mar 24
Annual report
4:21pm
10-K
EX-97.1
nomsp5zv6fghj
28 Mar 24
Annual report
4:21pm
8-K
EX-99.1
gnakepa7fnxck2l4k
28 Mar 24
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
4:08pm
8-K
EX-99.1
nzouo
11 Mar 24
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
8:05am
8-K
EX-99.2
w7rqtrnq1rgy
11 Mar 24
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
8:05am
8-K
EX-99.3
b1boi70fr3n
11 Mar 24
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
8:05am
8-K
EX-99.1
1nlsu28r0v8cn46
27 Nov 23
ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program
4:31pm